With 3.12 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.03 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.5 whereas the lowest price it dropped to was $3.53. The 52-week range on PBM shows that it touched its highest point at $82.49 and its lowest point at $2.36 during that stretch. Beta for the stock currently stands at 0.23.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PBM was up-trending over the past week, with a rise of 43.69%, but this was up by 57.45% over a month. Three-month performance dropped to -10.48% while six-month performance rose 26.50%. The stock lost -73.60% in the past year, while it has lost -92.58% so far this year.
Float and Shares Shorts:
On 2025-09-15, short shares totaled 38264.0, which was 1632.9999999999998 higher than short shares on 1755216000. In addition to Mr. Jody Aufrichtig as the firm’s Co-Founder, Executive Chairman & Strategic Business Development Officer, Dr. Neil Maresky M.D. serves as its CEO & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, PBM reported revenue of $0.0 and operating income of -$1157118.0. The EBITDA in the recently reported quarter was $327929.0 and diluted EPS was $4.0647.
